EPS for Advaxis, Inc. (ADXS) Expected At $-0.41 as of June, 5

May 17, 2018 - By Vernon Prom

Advaxis, Inc. (NASDAQ:ADXS) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.12. That’s change of 0.11, from 2017Q3’s 1.23. 17 investors sold all, 17 reduced holdings as Advaxis, Inc. ratio turned negative. 22 increased stakes while 16 funds bought stakes. Funds hold 15.17 million shares thus 10.45% less from 2017Q3’s 16.94 million shares.
Bancshares Of Montreal Can holds 0% in Advaxis, Inc. (NASDAQ:ADXS) or 433,198 shs. Victory Cap Management holds 0% or 5,316 shs in its capital. Wolverine Asset Management Ltd Liability Company stated it has 0% in Advaxis, Inc. (NASDAQ:ADXS). Edge Wealth Mgmt Limited Liability invested in 850 shs. American Century Companies has 18,211 shs. 66,206 were accumulated by Wells Fargo And Mn. 542,230 were accumulated by Fmr Ltd Liability Co. Citadel Limited Liability Corp invested 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS). Financial Bank Of New York Mellon holds 140,875 shs or 0% of its capital. State Of Wisconsin Invest Board stated it has 31,000 shs or 0% of all its holdings. Tiaa Cref Inv Mngmt Limited Liability Corp holds 105,059 shs. Morgan Stanley reported 178,381 shs stake. Focused Wealth Mgmt Inc holds 0% or 275 shs. Bnp Paribas Arbitrage owns 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 8,156 shs. California State Teachers Retirement invested in 0% or 58,649 shs.

Advaxis, Inc. had 3 insider sales and 0 insider buys since December 29, 2017. This’s net activity of $20,259. On Friday, December 29 Bonstein Sara had sold 5,224 shs worth $16,612. Another trade for 32 shs valued at $94 was sold by LOMBARDO ANTHONY A.

Earnings report for Advaxis, Inc. (NASDAQ:ADXS) is anticipated on June, 5., as reported by RTT. This year’s earnings per share analyst estimate is anticipated to be $-0.41. That is 19.61 % up compareed to $-0.51 earnings per share for last year. After $-0.49 earnings per share was published previous quarter, analysts now see EPS growth of -16.33 % for Advaxis, Inc.. Ticker’s shares touched $1.87 during the last trading session after 6.50% change.Advaxis, Inc. has volume of 753,197 shares. Since May 17, 2017 ADXS has declined 77.70% and is downtrending. ADXS underperformed by 89.25% the S&P 500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

A total of 2 analysts rate Advaxis (NASDAQ:ADXS) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ADXS) has 3 ratings reports on May 17, 2018 according to StockzIntelligence. On Tuesday, March 13 Cantor Fitzgerald maintained Advaxis, Inc. (NASDAQ:ADXS) with “Overweight” rating. On Wednesday, March 14 the firm has “Buy” rating given by H.C. Wainwright. On Wednesday, December 27 H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) rating. H.C. Wainwright has “Buy” rating and $23.0 target.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.The firm is worth $97.83 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer.Last it reported negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Another two news for Advaxis, Inc. (NASDAQ:ADXS) were recently brought out by: Nasdaq.com on May 14, 2018 with title “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …”. The other Streetinsider.com‘s article was titled “Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy” and brought out on May 11, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: